surmount-1 tirzepatide trial obesity without diabetes For the first time, and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults with obesity, no diabetes. 72 weeks. Both drugs at maximum tolerated dose. The Efficacy and safety of once-weekly

Once your work boots wear out, theyll need to be replaced if repairing them cant bring them back to their original condition

Both trials implemented similar inclusion and exclusion criteria and had similar baseline populations

Both are fine as long as the color is uniform and the solution is clear (transparent, not cloudy)

For nausea , the most frequently reported side effect, several approaches prove helpful

Acupuncture While the evidence base is mixed, acupuncture has shown benefits for various neuropathic pain conditions

For 503B outsourcing facilities (larger-scale compounding operations), the deadline was March 2025